Peptide:MHC dependent activation of natural killer cells through KIR2DS2 generates anti-tumor responses
P. Rettman, M. D. Blunt, B. Mbiribindi, R. Fulton, R. Schittenhelm, A. F. Vallejo, L. Bastidas-Legarda, M. E. Polak, R. Ayala, A. W. E. Purcell, A. Al-Shamkhani, C. Retiere, S. I. Khakoo
This study shows that activating NK cells via KIR2DS2 with a peptide:MHC vaccine generates anti-tumor responses and identifies XPO1 as a cancer-associated ligand for KIR2DS2.
bioRxiv · Apr 15, 2020 · PreprintImmunology